In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited. Here we examine the possibility that assessment of endogenous catecholamine levels in cerebrospinal fluid (CSF) may fuel new therapeutic strategies. In reviewing the available literature, we consider the effects of levodopa, monoamine oxidase inhibitors, and noradrenaline (NE) modulators, showing disparate results. We present a preliminary assessment of CSF concentrations of dopamine (DA) and NE, determined by HPLC, in a small dementia cohort of either Alzheimer's disease (AD) or frontotemporal dementia patients, compared to control subjects. Our data reveal detectable levels of DA, NE in CSF, though we found no significant alterations in the dementia population as a whole. AD patients exhibit a small impairment of the DA axis and a larger increase of NE concentration, likely to represent a compensatory mechanism. While waiting for preventive strategies, a pragmatic approach to AD may re-evaluate catecholamine modulation, possibly stratified to dementia subtypes, as part of the therapeutic armamentarium.

Stefani, A., Olivola, E., Liguori, C., Hainsworth, A., Saviozzi, V., Angileri, G., et al. (2015). Catecholamine-based treatment in AD patients: expectations and delusions. FRONTIERS IN AGING NEUROSCIENCE, 7(67) [10.3389/fnagi.2015.00067].

Catecholamine-based treatment in AD patients: expectations and delusions

STEFANI, ALESSANDRO;OLIVOLA, ENRICA;LIGUORI, CLAUDIO;ANGILERI, GIACOMA;D'ANGELO, VINCENZA;GALATI, SALVATORE;Pierantozzi, M.
2015-01-01

Abstract

In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited. Here we examine the possibility that assessment of endogenous catecholamine levels in cerebrospinal fluid (CSF) may fuel new therapeutic strategies. In reviewing the available literature, we consider the effects of levodopa, monoamine oxidase inhibitors, and noradrenaline (NE) modulators, showing disparate results. We present a preliminary assessment of CSF concentrations of dopamine (DA) and NE, determined by HPLC, in a small dementia cohort of either Alzheimer's disease (AD) or frontotemporal dementia patients, compared to control subjects. Our data reveal detectable levels of DA, NE in CSF, though we found no significant alterations in the dementia population as a whole. AD patients exhibit a small impairment of the DA axis and a larger increase of NE concentration, likely to represent a compensatory mechanism. While waiting for preventive strategies, a pragmatic approach to AD may re-evaluate catecholamine modulation, possibly stratified to dementia subtypes, as part of the therapeutic armamentarium.
2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Alzheimer's disease; Catecholamine; CSF; Dopamine; Monoaminooxidase inhibitors;
Alzheimer catecholamine CSF dopamine
Stefani, A., Olivola, E., Liguori, C., Hainsworth, A., Saviozzi, V., Angileri, G., et al. (2015). Catecholamine-based treatment in AD patients: expectations and delusions. FRONTIERS IN AGING NEUROSCIENCE, 7(67) [10.3389/fnagi.2015.00067].
Stefani, A; Olivola, E; Liguori, C; Hainsworth, A; Saviozzi, V; Angileri, G; D'Angelo, V; Galati, S; Pierantozzi, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
catecholamine frontier.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 140.28 kB
Formato Adobe PDF
140.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/171298
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 22
social impact